{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:36:47Z","timestamp":1790689007541,"version":"4.1.0"},"reference-count":94,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Introduction: Due to its aggressiveness, cutaneous melanoma (CM) is responsible for most skin cancer-related deaths worldwide. The origin of CM is closely linked to the appearance of UV-induced somatic mutations in melanocytes present in normal skin or in CM precursor lesions (nevi or dysplastic nevi). In recent years, new NGS studies performed on CM tissue have increased the understanding of the genetic somatic changes underlying melanomagenesis and CM tumor progression. Methods: We reviewed the literature using all important scientific databases. All articles related to genomic mutations in CM as well as normal skin and nevi were included, in particular those related to somatic mutations produced by UV radiation. Conclusions: CM development and progression are strongly associated with exposure to UV radiation, although each melanoma subtype has different characteristic genetic alterations and evolutionary trajectories. While BRAF and NRAS mutations are common in the early stages of tumor development for most CM subtypes, changes in CDKN2A, TP53 and PTEN, together with TERT promoter mutations, are especially common in advanced stages. Additionally, large genome duplications, loss of heterozygosity, and copy number variations are hallmarks of metastatic disease. Finally, the mutations driving melanoma targeted-therapy drug resistance are also summarized. The complete sequential stages of clonal evolution leading to CM onset from normal skin or nevi are still unknown, so further studies are needed in this field to shed light on the molecular pathways involved in CM malignant transformation and in melanoma acquired drug resistance.<\/jats:p>","DOI":"10.3390\/life12091339","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T22:53:42Z","timestamp":1661813622000},"page":"1339","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["UV-Induced Somatic Mutations Driving Clonal Evolution in Healthy Skin, Nevus, and Cutaneous Melanoma"],"prefix":"10.3390","volume":"12","author":[{"given":"Alba","family":"Loras","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Valencia, 46010 Valencia, Spain"},{"name":"Department of Medicine, Jaume I University of Castellon, 12071 Castellon, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gil-Barrachina","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jaume I University of Castellon, 12071 Castellon, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Marqu\u00e9s-Torrej\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jaume I University of Castellon, 12071 Castellon, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Perez-Pastor","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Valencia General University Hospital, 46014 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5252-563X","authenticated-orcid":false,"given":"Conrado","family":"Martinez-Cadenas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jaume I University of Castellon, 12071 Castellon, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Cherepakhin, O.S., Argenyi, Z.B., and Moshiri, A.S. (2021). Genomic and Transcriptomic Underpinnings of Melanoma Genesis, Progression, and Metastasis. Cancers, 14.","DOI":"10.3390\/cancers14010123"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kontogianni, G., Piroti, G., Maglogiannis, I., Chatziioannou, A., and Papadodima, O. (2018). Dissecting the Mutational Landscape of Cutaneous Melanoma: An Omic Analysis Based on Patients from Greece. Cancers, 10.","DOI":"10.3390\/cancers10040096"},{"key":"ref_3","first-page":"300","article-title":"Histopathologic Classification and Prognostic Factors of Melanoma: A 2021 Update","volume":"156","author":"Bobos","year":"2021","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2020.11.023","article-title":"The Effect of Age on the Acquisition and Selection of Cancer Driver Mutations in Sun-Exposed Normal Skin","volume":"32","author":"Hernando","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41525-017-0030-7","article-title":"Characterisation of the Changing Genomic Landscape of Metastatic Melanoma Using Cell Free DNA","volume":"2","author":"Cutts","year":"2017","journal-title":"NPJ Genom. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/bjd.20421","article-title":"Melanoma Genomics: A State-of-the-Art Review of Practical Clinical Applications","volume":"185","author":"Guhan","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/bjd.19128","article-title":"Molecular Subtype, Biological Sex and Age Shape Melanoma Tumour Evolution","volume":"184","author":"Lotz","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of Mutational Processes in Human Cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10555-016-9613-5","article-title":"Genetic Progression of Malignant Melanoma","volume":"35","author":"Vizkeleti","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"eabd7703","DOI":"10.1126\/sciadv.abd7703","article-title":"Ultradeep Sequencing Differentiates Patterns of Skin Clonal Mutations Associated with Sun-Exposure Status and Skin Cancer Burden","volume":"7","author":"Wei","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1126\/science.aaa6806","article-title":"Tumor Evolution. High Burden and Pervasive Positive Selection of Somatic Mutations in Normal Human Skin","volume":"348","author":"Martincorena","year":"2015","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1126\/science.aab4082","article-title":"Somatic Mutation in Cancer and Normal Cells","volume":"349","author":"Martincorena","year":"2015","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/php.12377","article-title":"UV Signature Mutations","volume":"91","author":"Brash","year":"2015","journal-title":"Photochem. Photobiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Anusewicz, D., Orzechowska, M., and Bednarek, A.K. (2021). Notch Signaling Pathway in Cancer\u2014Review with Bioinformatic Analysis. Cancers, 13.","DOI":"10.3390\/cancers13040768"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2021.12659","article-title":"Role of FAT1 in Health and Disease (Review)","volume":"21","author":"Peng","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41418-022-00962-9","article-title":"Should Mutant TP53 Be Targeted for Cancer Therapy?","volume":"29","author":"Wang","year":"2022","journal-title":"Cell Death Differ."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-020-2785-8","article-title":"The Genomic Landscapes of Individual Melanocytes from Human Skin","volume":"586","author":"Tang","year":"2020","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/his.13843","article-title":"Massively Parallel Sequencing Analysis of Benign Melanocytic Naevi","volume":"75","author":"Lozada","year":"2019","journal-title":"Histopathology"},{"key":"ref_20","unstructured":"Macneal, P., and Patel, B.C. (2022). Congenital Melanocytic Nevi. StatPearls, StatPearls Publishing."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/pcmr.12412","article-title":"Genetics of Melanocytic Nevi","volume":"28","author":"Roh","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Testa, U., Castelli, G., and Pelosi, E. (2017). Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. Med. Sci., 5.","DOI":"10.3390\/medsci5040028"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"635316","DOI":"10.3389\/fmed.2021.635316","article-title":"On Naevi and Melanomas: Two Sides of the Same Coin?","volume":"8","author":"Lee","year":"2021","journal-title":"Front. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jid.2017.03.040","article-title":"The Natural History of Common Melanocytic Nevi: A Systematic Review of Longitudinal Studies in the General Population","volume":"137","author":"Plasmeijer","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/bjd.15809","article-title":"The BRAF and NRAS Mutation Prevalence in Dermoscopic Subtypes of Acquired Naevi Reveals Constitutive Mitogen-Activated Protein Kinase Pathway Activation","volume":"178","author":"Tan","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1046\/j.0022-202X.2004.22225.x","article-title":"BRAF Mutations Are Common Somatic Events in Melanocytic Nevi","volume":"122","author":"Kumar","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/jcp.2004.019422","article-title":"Melanocytic Dysplastic Naevi Occupy the Middle Ground between Benign Melanocytic Naevi and Cutaneous Malignant Melanomas: Emerging Clues","volume":"58","author":"Hussein","year":"2005","journal-title":"J. Clinical Pathology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jid.2016.11.017","article-title":"Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma","volume":"137","author":"Melamed","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"635488","DOI":"10.3389\/fonc.2021.635488","article-title":"Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies","volume":"11","author":"Scatena","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhao, Y., and Ma, S. (2016). Racial Differences in Six Major Subtypes of Melanoma: Descriptive Epidemiology. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2747-6"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jnci\/djy086","article-title":"Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy","volume":"111","author":"Lattanzi","year":"2019","journal-title":"JNCI J. Nation Cancer Inst."},{"key":"ref_32","unstructured":"Elder, D.E., Massi, D., Scoyler, R.A., and Willemze, R. (2018). WHO Classification of Skin Tumours, IARC Publications. [4th ed.]."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"914267","DOI":"10.1155\/2012\/914267","article-title":"Diagnostic Role of Chromosomal Instability in Melanoma","volume":"2012","author":"Dabas","year":"2012","journal-title":"J. Skin Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2217\/mmt.15.3","article-title":"Lentigo Maligna and Lentigo Maligna Melanoma: Contemporary Issues in Diagnosis and Management","volume":"2","author":"Connolly","year":"2015","journal-title":"Melanoma Manag."},{"key":"ref_35","unstructured":"Xiong, M., Charifa, A., and Chen, C.S.J. (2022). Lentigo Maligna Melanoma. StatPearls, StatPearls Publishing."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0002-9440(10)63536-5","article-title":"Classifying Melanocytic Tumors Based on DNA Copy Number Changes","volume":"163","author":"Bastian","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/pcmr.12851","article-title":"Tumor Genetic Heterogeneity Analysis of Chronic Sun-Damaged Melanoma","volume":"33","author":"Sanna","year":"2020","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5826\/dpc.0402a15","article-title":"Nodular Melanoma: Five Consecutive Cases in a General Practice with Polarized and Non-Polarized Dermatoscopy and Dermatopathology","volume":"4","author":"Rosendahl","year":"2014","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaad.2020.11.047","article-title":"Five-Year Survival in Patients with Nodular and Superficial Spreading Melanomas in the US Population","volume":"84","author":"Allais","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","unstructured":"Cancer Genome Atlas Network (2015). Genomic Classification of Cutaneous Melanoma. Cell, 161, 1681\u20131696."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.hoc.2020.08.010","article-title":"Biology of Melanoma","volume":"35","author":"Ostrowski","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The Genetic Evolution of Melanoma from Precursor Lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-13-0398","article-title":"BRAF\/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage","volume":"19","author":"Mar","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ijc.2910520207","article-title":"Progression of Human Cutaneous Melanoma Is Associated with Loss of Expression of C-Kit Proto-Oncogene Receptor","volume":"52","author":"Natali","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/pcmr.12544","article-title":"Metastatic Pathways in Patients with Cutaneous Melanoma","volume":"30","author":"Adler","year":"2017","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/jid.2014.163","article-title":"TERT Promoter Mutations in Skin Cancer: The Effects of Sun Exposure and X-Irradiation","volume":"134","author":"Boaventura","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ccell.2018.05.014","article-title":"Bi-Allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation","volume":"34","author":"Zeng","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00428-015-1784-x","article-title":"Coexistence of TERT Promoter and BRAF Mutations in Cutaneous Melanoma Is Associated with More Clinicopathological Features of Aggressiveness","volume":"467","author":"Macerola","year":"2015","journal-title":"Virchows Arch."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1023\/A:1006304806799","article-title":"Cell Adhesion Molecules in the Development and Progression of Malignant Melanoma","volume":"18","author":"Johnson","year":"1999","journal-title":"Cancer Metastasis Rev."},{"key":"ref_51","first-page":"188","article-title":"Shifts in Cadherin Profiles between Human Normal Melanocytes and Melanomas","volume":"1","author":"Hsu","year":"1996","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00008390-199604000-00007","article-title":"E-Cadherin Expression in Human Melanoma","volume":"6","author":"Danen","year":"1996","journal-title":"Melanoma Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41467-021-21576-8","article-title":"Evolution of Late-Stage Metastatic Melanoma Is Dominated by Aneuploidy and Whole Genome Doubling","volume":"12","author":"Vergara","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1158\/0008-5472.CAN-15-3476","article-title":"Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma","volume":"76","author":"Harbst","year":"2016","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/35096061","article-title":"The INK4a\/ARF Network in Tumour Suppression","volume":"2","author":"Sherr","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Orlova, K.V., Ledin, E.V., Zhukova, N.V., Orlova, R.V., Karabina, E.V., Volkonskiy, M.V., Stroyakovskiy, D.L., Yurchenkov, A.N., Protsenko, S.A., and Novik, A.V. (2021). Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE). Cancers, 13.","DOI":"10.3390\/cancers13112529"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/pcmr.12459","article-title":"The Genomic Landscape of Cutaneous Melanoma","volume":"29","author":"Zhang","year":"2016","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Ruiz-Garcia, E., and Astudillo-de la Vega, H. (2019). Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics, Springer International Publishing. Advances in Experimental Medicine and Biology.","DOI":"10.1007\/978-3-030-24100-1"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Patel, M., Eckburg, A., Gantiwala, S., Hart, Z., Dein, J., Lam, K., and Puri, N. (2021). Resistance to Molecularly Targeted Therapies in Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13051115"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4068\/cmj.2017.53.3.173","article-title":"Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma","volume":"53","author":"Ryu","year":"2017","journal-title":"Chonnam Med. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in Patients with BRAF-Mutant Melanoma (COLUMBUS): A Multicentre, Open-Label, Randomised Phase 3 Trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the CoBRIM Study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(13)70237-7","article-title":"Selumetinib plus Dacarbazine versus Placebo plus Dacarbazine as First-Line Treatment for BRAF-Mutant Metastatic Melanoma: A Phase 2 Double-Blind Randomised Study","volume":"14","author":"Robert","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Lebb\u00e9, C., Dutriaux, C., Lesimple, T., Kruit, W., Kerger, J., Thomas, L., Guillot, B., de Braud, F., Garbe, C., and Grob, J.-J. (2020). Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. Cancers, 12.","DOI":"10.3390\/cancers12071727"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3349\/ymj.2020.61.7.562","article-title":"KIT and Melanoma: Biological Insights and Clinical Implications","volume":"61","author":"Pham","year":"2020","journal-title":"Yonsei Med. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9235638","DOI":"10.1155\/2020\/9235638","article-title":"Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions","volume":"2020","author":"Ralli","year":"2020","journal-title":"J. Immunol. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-14-0776","article-title":"FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation","volume":"20","author":"Kim","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17460441.2016.1201057","article-title":"The Discovery of Vemurafenib for the Treatment of BRAF-Mutated Metastatic Melanoma","volume":"11","author":"Kim","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.2147\/OTT.S325208","article-title":"Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice","volume":"14","author":"Ochenduszko","year":"2021","journal-title":"OTT"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.critrevonc.2018.03.005","article-title":"Recent Developments and Obstacles in the Treatment of Melanoma with BRAF and MEK Inhibitors","volume":"125","author":"Wahid","year":"2018","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1358\/dot.2019.55.4.2958476","article-title":"Encorafenib and Binimetinib for the Treatment of BRAF V600E\/K-Mutated Melanoma","volume":"55","author":"Rose","year":"2019","journal-title":"Drugs Today"},{"key":"ref_74","first-page":"741","article-title":"Trametinib: A Targeted Therapy in Metastatic Melanoma","volume":"9","author":"Hoffner","year":"2018","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1517\/14656566.2016.1168806","article-title":"Cobimetinib and Vemurafenib for the Treatment of Melanoma","volume":"17","author":"Boespflug","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","article-title":"Tivantinib for Second-Line Treatment of MET-High, Advanced Hepatocellular Carcinoma (METIV-HCC): A Final Analysis of a Phase 3, Randomised, Placebo-Controlled Study","volume":"19","author":"Rimassa","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ejphar.2019.04.010","article-title":"Molecular Targets for Tivantinib (ARQ 197) and Vasculogenic Mimicry in Human Melanoma Cells","volume":"853","author":"Kumar","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/bjc.2016.419","article-title":"Phase II Randomised Discontinuation Trial of the MET\/VEGF Receptor Inhibitor Cabozantinib in Metastatic Melanoma","volume":"116","author":"Daud","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/CAD.0000000000000033","article-title":"Axitinib, a Selective Inhibitor of Vascular Endothelial Growth Factor Receptor, Exerts an Anticancer Effect in Melanoma through Promoting Antitumor Immunity","volume":"25","author":"Zhang","year":"2014","journal-title":"Anticancer Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1200\/JCO.19.00210","article-title":"Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial","volume":"37","author":"Sheng","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib Blocks the RAF\/MEK\/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"20411","DOI":"10.1073\/pnas.0905833106","article-title":"MEK1 Mutations Confer Resistance to MEK and B-RAF Inhibition","volume":"106","author":"Emery","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.02.003","article-title":"Inhibiting Drivers of Non-Mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy","volume":"29","author":"Smith","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"ra84","DOI":"10.1126\/scisignal.2001148","article-title":"BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation","volume":"3","author":"Corcoran","year":"2010","journal-title":"Sci. Signal."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1593\/neo.04532","article-title":"A Role for K-Ras in Conferring Resistance to the MEK Inhibitor, CI-1040","volume":"7","author":"Wang","year":"2005","journal-title":"Neoplasia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1158\/0008-5472.CAN-10-3647","article-title":"STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA MiR-17","volume":"71","author":"Dai","year":"2011","journal-title":"Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"41387","DOI":"10.18632\/oncotarget.17866","article-title":"Induction of Immunoglobulin Transcription Factor 2 and Resistance to MEK Inhibitor in Melanoma Cells","volume":"8","author":"Hur","year":"2017","journal-title":"Oncotarget"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for Combining Targeted and Conventional Cancer Therapy with Immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted Agents and Immunotherapies: Optimizing Outcomes in Melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, Vemurafenib, and Cobimetinib as First-Line Treatment for Unresectable Advanced BRAFV600 Mutation-Positive Melanoma (IMspire150): Primary Analysis of the Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/fon-2018-0607","article-title":"Nivolumab and Ipilimumab: Immunotherapy for Treatment of Malignant Melanoma","volume":"15","author":"Carreau","year":"2019","journal-title":"Future Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/cam4.1356","article-title":"Peripheral Blood Clinical Laboratory Variables Associated with Outcomes Following Combination Nivolumab and Ipilimumab Immunotherapy in Melanoma","volume":"7","author":"Rosner","year":"2018","journal-title":"Cancer Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbcan.2019.02.002","article-title":"Many Ways to Resistance: How Melanoma Cells Evade Targeted Therapies","volume":"1871","author":"Kozar","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/9\/1339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:19:28Z","timestamp":1760141968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/9\/1339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":94,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["life12091339"],"URL":"https:\/\/doi.org\/10.3390\/life12091339","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]}}}